LiDCO Group Plc

("LiDCO" or the "Company")

US FDA clears for sale LiDCOrapid^v2 with Depth of Anesthesia display

LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, is pleased to announce that the US Food and Drug Administration (FDA) has cleared its new LiDCOrapid^v2 monitor with Unity software and depth of anesthesia display for sale in the US. The US is the world's largest single market for fluid management and disposables use during high risk surgery with a market potential of approximately $650 million per annum. This registration follows on from the registration and launch of the LiDCOrapid^v2 in the EU in February of this year.  LiDCOrapid^v2 sales have already been made in both the UK and the EU with a highly positive reaction from customers.

The LiDCOrapid^v2 with Unity software is the first monitor in the world to be designed specifically for multi-parameter monitoring of both depth of anesthesia and fluids. The Unity software allows the connection of Covidien's BIS^TM LOC 2 channel module to the LiDCOrapid^v2 to co-display Covidien's depth of anesthesia parameter (BIS) alongside fluid monitoring. LiDCO believes that there is a trend within hospitals to move towards single devices that perform multiple functions. Through parameter integration, LiDCO's new monitor addresses a growing requirement for a multi-parameter display that reduces the number of single parameter monitors needed by the bedside.

Additional parameters can easily be added to further increase the breadth of monitoring displayed on the LiDCOrapid^v2. LiDCO expect its additional continuous non invasive blood pressure monitoring option to be registered for sale in the US later this year.

The LiDCOrapid^v2 with Unity software satisfies UK NICE (National Institute for Health and Clinical Excellence) recommendations for both the monitoring of fluids and depth of anesthesia in high risk surgery patients. From April 2013 the NHS in England will be providing payment incentives aiming to significantly increase the numbers of surgery patients that are fluid monitored from approximately 40,000 to 80,000 patients per year. The Board estimates that this equates to an additional £2.8 million of possible revenues.

Terry O'Brien, Chief Executive Officer of LiDCO, commented: "LiDCO's PC based monitor LiDCOrapid^v2 is a multi-parameter platform that can address the potential global high risk surgery disposable market of $2 billion per annum. The US clearance for sale of LiDCO's new monitor, which combines fluid monitoring and depth of anesthesia in a single display, allows the Company to commence sales in the world's largest fluid market for these parameters. The Board estimates that 3.4 million patients are suitable for monitoring in the US alone. The next near term milestone for LiDCO in the US will be the additional registration for the display of the non-invasive blood pressure module option that, when available, is expected to substantially further expand LiDCO's market opportunity."

Notes:

BIS and Bispectral Index are trademarks of Covidien LP registered in the U.S. and foreign countries, for more information on BIS products see: www.covidien.com.

- ENDS -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

* CNAP^TM is a trademark of CNSystems Medizintechnik AG.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.